Abstract
A new codelivery system combining prodrug strategy, siRNA/BAplatin @CRGDKNPs, to overcome cisplatin (CDDP) resistance in human breast cancer was designed and researched. Negatively charged siRNA was deposited onto the surface of tumor-targeting peptide-functionalized BAplatin@CRGDK NPs. SiRNA/BAplatin@CRGDK NPs could facilitate cellular uptake of BAplatin and increase the cell proliferation suppression effect of Pt against MDA-MB-231/DDP cells. The tumor-to-kidney uptake ratio of the siRNA/BAplatin@CRGDK NPs in MB-231/DDP tumors is 2.4-fold higher than that of cisplatin in MB-231/DDP tumors, thus giving rise to more significant antitumor efficacy. It demonstrated that the siRNA/BAplatin@CRGDK NPs is a potential, safe, and efficient therapeutic agent for cancer therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
